Nirav Shah, MD
Nirav Shah, MD, MSHP, is an Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital since 2015. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015. His research focus involves the development of novel treatments for B-cell malignancies and is currently leading several trials utilizing a novel agents and next generation CAR T-cell therapies.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Loxo-LillyTopic:Consulting/Advisory Board/TravelDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Miltenyi BiotecTopic:Consulting/Advisory Board/TravelDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KiteTopic:Advisory BoardDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:IncyteTopic:ConsultingDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenTopic:Advisory BoardDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BMS-JunoTopic:Advisory BoardDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Seattle GeneticsTopic:Advisory BoardDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:TG TherapeuticsTopic:Advisory BoardDate added:03/19/2023Date updated:05/07/2024
-
Attribution:SelfType of financial relationship:StockIneligible company:Tundra TherapeuticsTopic:Founder/Scientific BoardDate added:03/19/2023Date updated:05/07/2024
-
Type of financial relationship:Independent contractorIneligible company:EpizymeTopic:Advisory BoardDate added:03/19/2023Date updated:05/07/2024